Skip to main content
SpringerLink
Log in

Management of arterial hypertension in obese patients

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Obesity prevalence is increasing. Obesity frequently coexists with—and can cause or worsen—arterial hypertension. However, no current guidelines provide specific recommendations. Antihypertensive drug treatment is indicated in most obese hypertensive patients, leading to the obvious question: what is the best drug treatment for this population? Some antihypertensive agents may have unwanted effects on the metabolic and hemodynamic abnormalities linking obesity and hypertension. Without adequate studies, recommendations for or against each class of antihypertensive agents are based on subjective criteria and pathophysiologic assumptions. Diuretics and β-blockers have unwanted effects, whereas calcium antagonists are metabolically neutral, and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may increase insulin sensitivity. The renin-angiotensin system in adipose tissue has been implicated in arterial hypertension, and sodium retention is central to obesity-related hypertension. Therefore, an ACE inhibitor or diuretic should be considered as first-line antihypertensive drug therapy in obesity-hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jordan J, Engeli S, Redon J, et al.: European Society of Hypertension Working Group on Obesity: background, aims and perspectives. J Hypertens 2007, 25:897–900.

    Article  PubMed  CAS  Google Scholar 

  2. Doll S, Paccaud F, Bovet P, et al.: Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002, 26:48–57.

    Article  PubMed  CAS  Google Scholar 

  3. Bramlage P, Pittrow D, Wittchen HU, et al.: Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904–910.

    Article  PubMed  Google Scholar 

  4. Frohlich ED: Clinical management of the obese hypertensive patient. Cardiol Rev 2002, 10:127–138.

    Article  PubMed  Google Scholar 

  5. Dentali F, Sharma AM, Douketis JD: Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 2005, 7:330–336.

    Article  PubMed  Google Scholar 

  6. Wenzel UO, Krebs C: Treatment of arterial hypertension in obese patients. Contrib Nephrol 2006, 151:230–242.

    Article  PubMed  Google Scholar 

  7. Rocchini AP: Cardiovascular regulation in obesity-induced hypertension. Hypertension 1992, 19(1 Suppl):I56–I60.

    PubMed  CAS  Google Scholar 

  8. Sharma AM: Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004, 44:12–19.

    Article  PubMed  CAS  Google Scholar 

  9. Boustany CM, Bharadwaj K, Daugherty A, et al.: Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004, 287:R943–R949.

    PubMed  CAS  Google Scholar 

  10. Wofford MR, Hall JE: Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004, 10:3621–3637.

    Article  PubMed  CAS  Google Scholar 

  11. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  12. Sharma AM, Rossner S: Who cares about the obese hypertensive patient? J Intern Med 2002, 251:369–371.

    Article  PubMed  CAS  Google Scholar 

  13. Engeli S, Sharma AM: Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 2002, 17:355–359.

    Article  PubMed  Google Scholar 

  14. Jones DW, Miller ME, Wofford MR, et al.: The effect of weight loss intervention on antihypertensive medication requirements in the Hypertension Optimal Treatment (HOT) study. Am J Hypertens 1999, 12(12 Pt 1–2):1175–1180.

    Article  PubMed  CAS  Google Scholar 

  15. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894:i–xii, 1–253.

  16. Sjostrom L, Lindroos AK, Peltonen M, et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683–2693.

    Article  PubMed  Google Scholar 

  17. Aucott L, Poobalan A, Smith WC, et al.: Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005, 45:1035–1041.

    Article  PubMed  CAS  Google Scholar 

  18. Basso N, Terragno NA: History about the discovery of the renin-angiotensin system. Hypertension 2001, 38:1246–1249.

    Article  PubMed  CAS  Google Scholar 

  19. Wenzel UO: Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. Contrib Nephrol 2001, 135:200–211.

    PubMed  CAS  Google Scholar 

  20. Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003, 93:P3–P13.

    Article  PubMed  CAS  Google Scholar 

  21. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.

    Article  PubMed  CAS  Google Scholar 

  22. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004, 64:2537–2565.

    Article  PubMed  CAS  Google Scholar 

  23. McFarlane SI, Provilus A, Shin JJ: Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Trial. J Cardiometab Syndr 2007, 2:149–150.

    Article  PubMed  Google Scholar 

  24. Sharma AM, Pischon T, Engeli S, Scholze J: Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001, 19:667–674.

    Article  PubMed  CAS  Google Scholar 

  25. Zanella MT, Kohlmann O Jr, Ribeiro AB: Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001, 38(3 Pt 2):705–708.

    PubMed  CAS  Google Scholar 

  26. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  27. Grassi G, Seravalle G, Dell’Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761–1769.

    Article  PubMed  CAS  Google Scholar 

  28. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  29. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799–812.

    Article  PubMed  CAS  Google Scholar 

  30. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  31. Benson SC, Pershadsingh HA, Ho CI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993–1002.

    Article  PubMed  CAS  Google Scholar 

  32. Schupp M, Janke J, Clasen R, et al.: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054–2057.

    Article  PubMed  CAS  Google Scholar 

  33. Schupp M, Lee LD, Frost N, et al.: Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006, 47:586–589.

    Article  PubMed  CAS  Google Scholar 

  34. Benndorf RA, Rudolph T, Appel D, et al.: Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006, 55:1159–1164.

    Article  PubMed  CAS  Google Scholar 

  35. Müller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221–228.

    Article  PubMed  CAS  Google Scholar 

  36. Huang Y, Wongamorntham S, Kasting J, et al.: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006, 69:105–113.

    Article  PubMed  CAS  Google Scholar 

  37. Krebs C, Hamming I, Sadaghiani S, et al.: Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007, Epub ahead of print.

  38. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet 2006, 368:1449–1456.

    Article  PubMed  CAS  Google Scholar 

  39. Jordan J, Engeli S, Boye SW, et al.: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047–1055.

    Article  PubMed  CAS  Google Scholar 

  40. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.

    Article  Google Scholar 

  41. Kostis JB, Wilson AC, Freudenberger RS, et al.: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005, 95:29–35.

    Article  PubMed  CAS  Google Scholar 

  42. Aksnes TA, Kjeldsen SE, Rostrup M, et al.: Impact of newonset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007, 50:467–473.

    Article  PubMed  CAS  Google Scholar 

  43. Wenzel UO: Aldosterone and progression of renal disease. Curr Opin Nephrol Hypertens 2007, In press.

  44. Calhoun DA: Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006, 48:387–396.

    Article  PubMed  CAS  Google Scholar 

  45. Saha C, Eckert GJ, Ambrosius WT, et al.: Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481–487.

    Article  PubMed  CAS  Google Scholar 

  46. Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250–254.

    PubMed  CAS  Google Scholar 

  47. Scholze J, Grimm E, Herrmann D, et al.: Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007, 115:1991–1998.

    Article  PubMed  CAS  Google Scholar 

  48. Lindholm LH, Carlberg B, Samuelsson O: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545–1553.

    Article  PubMed  CAS  Google Scholar 

  49. Schmieder RE, Gatzka C, Schachinger H, et al.: Obesity as a determinant for response to antihypertensive treatment. BMJ 1993, 307:537–540.

    PubMed  CAS  Google Scholar 

  50. White WB, Elliott WJ, Johnson MF, Black HR: Chrono-therapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 2001, 15:135–141.

    Article  PubMed  CAS  Google Scholar 

  51. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895–906.

    Article  PubMed  CAS  Google Scholar 

  52. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415–420.

    Article  PubMed  CAS  Google Scholar 

  53. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967–1975.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. III Medizinische Klinik, Universitätsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany

    Ulrich O. Wenzel

Authors
  1. Ulrich O. Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Krebs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich O. Wenzel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wenzel, U.O., Krebs, C. Management of arterial hypertension in obese patients. Current Science Inc 9, 491–497 (2007). https://doi.org/10.1007/s11906-007-0090-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0090-7

Keywords

Search

Navigation